TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02561234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-ArgI-PEG
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-ArgI-PEG
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-ArgI-PEG
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-ArgI-PEG
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-ArgI-PEG
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-ArgI-PEG
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-ArgI-PEG
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-ArgI-PEG
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-ArgI-PEG
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-ArgI-PEG
Description: Administered IV
Study: NCT03259685

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 710 ml of regular soft drinks, taken daily for 10 weeks
Description: Subjects will consume regular soft drinks to test if there is a significant difference on the impact on gut microbiota composition and metabolic syndrome parameters between this treatment and the active treatments (diet and stevia beverages).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 710 ml of diet soft drinks, taken daily for 10 weeks
Description: Subjects will consume diet soft drinks during 10 weeks to test the possible effects of aspartame/acesulfame-K sweetened beverages on gut microbiota composition and on metabolic syndrome parameters.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 710 ml of stevia-sweetened soft drinks, taken daily for 10 weeks
Description: Subjects will consume soft drinks containing stevia during 10 weeks to test the possible effects of steviol glycosides sweetened beverages on gut microbiota composition and on metabolic syndrome parameters.
Study: NCT03146273

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamins
Description: After the study product administration blood tests will be performed in order to calculate the AUC for each mineral and vitamin - Vit A Vit E Folic Acid Vit C Calcium Magnesium~After the washout period, the same procedure will be done for the additional formulation of the multivitamins.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamins
Description: After the study product administration blood tests will be performed in order to calculate the AUC for each mineral and vitamin - Vit A Vit E Folic Acid Vit C Calcium Magnesium~After the washout period, the same procedure will be done for the additional formulation of the multivitamins.
Study: NCT03997786

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tildrakizumab
Description: Week 0 (Day 1), Week 4 (Day 28) and week 16 (Day 112)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: (Weeks 0 to 16)
Study: NCT03974854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOXIRI-3
Description: chemotherapy with XELOXIRI-3 regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: chemotherapy with Gemcitabine regimen
Study: NCT01286233

Intervention type: DRUG
Intervention: Metformin

Intervention type: DRUG
Intervention: Placebo
Study: NCT02118883

Intervention type: OTHER
Group type: OTHER
Intervention: Essentia Water

Intervention type: OTHER
Group type: OTHER
Intervention: Bottled water
Study: NCT04465110

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Grape Seed Extract
Description: Subjects took a single dose of 600 mg GSE in capsule form through ingestion 2 hours prior to testing Dietary Supplement: Grape seed extract Two capsule grape seed extract (total 600 mg) per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Grape Seed Extract
Description: Subjects took a single dose of 600 mg GSE in capsule form through ingestion 2 hours prior to testing Dietary Supplement: Grape seed extract Two capsule grape seed extract (total 600 mg) per day
Study: NCT02272426

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CARET
Description: Combined Aerobic and Resistance Exercise Training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CTI
Description: Cognitive Training Intervention

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham CARET
Description: Sham Combined Aerobic and Resistance Exercise Training

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham CTI
Description: Sham Cognitive Training Intervention
Study: NCT01522248

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent Inactivated Influenza vaccine
Description: 0.5 ml IM once only

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent Inactivated Influenza vaccine
Description: 0.5 ml IM once only
Study: NCT03719586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZMapp
Description: Three doses of 50 mg/kg of body weight administered intravenously every third day beginning on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Administered intravenously with a loading dose on Day 1 (200 mg for adults and pediatric patients with body weight \>= 40 kg and for pediatric patients weighing \< 40 kg one loading dose of remdesivir 5 mg/kg) followed by 9 to 13 days of once-daily maintenance dosing starting on Day 2 and extending through Day 10 to 14 (100 mg for adults and pediatric patients with body weight \>= 40 kg and for pediatric patients weighing \< 40 kg remdesivir 2.5 mg/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAb114
Description: 50 mg/kg of body weight administered intravenously on Day 1 as a single infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN-EB3
Description: 150 mg/kg of body weight administered intravenously on Day 1 as a single infusion
Study: NCT03713892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-504
Description: orally administered once with investigational drug assigned on 1d morning with 240 mL of water

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orally administered
Study: NCT01360593

Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine
Description: Gemcitabine will be administered for 2 weekly doses every 3 weeks commencing 12 weeks prior to stereotactic radiosurgery as follows:~Gemcitabine 1,000 mg/m2 IV over 30 minutes on Day 1, and 8 of 21- day cycle. This will be done for up to 4 cycles.

Intervention type: DRUG
Group type: OTHER
Intervention: Capecitabine
Description: Capecitabine will be taken orally twice daily on days 1-14 every 3 weeks for 4 cycles (12 weeks) prior to stereotactic radiosurgery as follows:~Capecitabine 650 mg/m2 twice daily for days 1-14 every 3 weeks for up to 4 cycles.

Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Fractionated SBRT will be delivered to patients that have stable disease, partial response, or complete response after chemo in the following manner:~12 Gy x 3 fractions (36 Gy total) This will be given every other day.
Study: NCT02639767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed/Cisplatin
Description: Dose escalation of pemetrexed and cisplatin will follow the dose levels. The escalation will not exceed 500 mg/m\^2 for pemetrexed in combination with 75 mg/m\^2 of cisplatin even if the maximum tolerated dose is not identified. Each treatment cycle of chemotherapy will be 21 days. Patients will receive up to 2 cycles of chemotherapy during the radiation, and be followed for any DLT during the radiation therapy and for 12 weeks afterwards.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pleural Intensity Modulated Radiation Therapy
Description: Pleura intensity modulated radiation therapy (IMRT) will be administered over approximately 6 weeks at 50.4 Gy in 28 fractions. The prescription radiation dose may anywhere between 45 and 50.4 Gy in 25 fractions if necessary to meet the normal tissue dose constraints.
Study: NCT03254914

Intervention type: PROCEDURE
Intervention: Home Blood Pressure
Description: Measure Home Blood Pressure
Study: NCT03224845

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural skills training
Description: The intervention will be delivered in two stages: First, the parent with an anxiety disorder will attend between six and sixteen weekly sessions of cognitive behavioural skills training focusing on their own anxiety. They will work on developing behaviours that will help them become less anxious in the long-run and on learning to evaluate danger in a realistic way. Next, the parent will take part in four to eight weekly sessions of anti-anxiety parenting skills training aiming to help them transfer the skills that they learned into parenting their children. In the parenting intervention, the parents will be guided to gradually expose their children to new situations, build communication skills and confidence, in addition to general parenting skills and principles.
Study: NCT04498533

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio tape application
Study: NCT01402284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Cycle 1: 20 mg/m(2) intravenous (IV) infusion over 30 minutes on days 1 and 2, then 36 mg/m(2) IV on days 8, 9, 15, and 16 Cycle 2-8: 36mg/ m(2) IV infusion over 30 minutes on days 1, 2, 8, 9, 15, and 16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Cycle 1: 25 mg oral days 2-21 of 28-day cycle; Cycle 2 - 8: 25 mg oral days 1-21 of 28-day cycle; After 8 cycles of combination carfilzomib, lenalidomide, and dexamethasone (CRd), patients may continue Lenalidomide for 12 cycles; After 12 cycles of extended dosing of Lenalidomide, patients may continue Lenalidomide for one year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Cycle 1: 20 mg oral or IV on days 2, 8, 9, 15, 16, 22, and 23 Cycle 2-4: 20 mg oral or IV on days 1, 2, 8, 9, 15, 16, 22, and 23 Cycle 5-8: 10 mg oral or IV on days 1, 2, 8, 9, 15, 16, 22, and 23

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: After 8 cycles of combination carfilzomib, lenalidomide, and dexamethasone (CRd), patients may continue Lenalidomide for 12 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: After 12 cycles of extended dosing of Lenalidomide, patients may continue Lenalidomide for one year
Study: NCT03816306

Intervention type: DRUG
Intervention: LCZ 696
Description: LCZ696 is an Angiotensin receptor neprilysin inhibitor. It's composed of Sacubitril/Valsartan. LCZ696 starting dose 50 mg P.O. BID, LCZ696 100 mg P.O. BID and up-titration to LCZ696 200 mg P.O. BID.
Study: NCT02290535

Intervention type: PROCEDURE
Intervention: patients
Description: The 16-electrode belt will be applied to patient's chest. Following vital signs will be recorded: respiratory rate at rest breathing, heart rate, transcutaneous oxygen saturation. Then impulse oscillometry (IOS) will be performed in a sitting position. After that, subjects with cooperation willingness will get a body plethysmography. A spirometry / forced breathing maneuvers will be performed. All patients will receive 2 strokes salbutamol inhaler for bronchospasmolysis. Please note that inhalation of salbutamol is not study related. It is used in the clinical routine to examine the reversibility of the bronchial obstruction in patients with obstructive lung disease in course of the lung function test. Ten minutes later measurements described above will be repeated.
Study: NCT02639767

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: A pre-treatment MRI before chemo-RT will be acquired and will be used for target delineation. A three month post-treatment MRI will be acquired with the same protocol to assess the response from concurrent chemo-RT.
Study: NCT03566784

Intervention type: PROCEDURE
Intervention: Inguinal hernia repair
Description: Standard procedure for inguinal hernia repair

Intervention type: PROCEDURE
Intervention: Inguinal hernia repair
Description: Standard procedure for inguinal hernia repair
Study: NCT02191137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY63-2521)
Description: Participants received therapy with riociguat during a 10-week titration phase. The starting dose for riociguat for all patients was 0.5 milligram (mg) three times a day (TID). The dose of riociguat was increased every 2 weeks in 0.5 mg increments to 1.0, 1.5, 2.0, and 2.5 mg until patients reached their individual optimal dose based on their systolic blood pressure and well-being. After reaching their optimal dose, patients then entered a maintenance phase and remained on this dose for an additional 14 weeks. End of treatment was reached at Visit 10 after 24 weeks of treatment with riociguat.
Study: NCT04560036

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: FAZA PET/MRI scan
Description: FAZA PET/MRI scan before and after the standard of care chemotherapy
Study: NCT00696800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa
Description: On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection of 150 μg (0.5 mL) Corifollitropin Alfa was administered in the abdominal wall.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RecFSH / Follitropin beta (Days 1 to 7)
Description: Daily SC injections with 200 IU fixed dose recFSH were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Corifollitropin alfa
Description: Pre-filled syringe containing an identical solution when compared to Corifollitropin Alfa. On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection was administered in the abdominal wall.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo RecFSH / follitropin beta
Description: Identical ready-for-use solution, but without the active ingedient, supplied in cartridges for SC injection with the Follistim Pen. Daily SC injections were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RecFSH / Follitropin beta (Days 8 to hCG)
Description: From Stimulation Day 8 onwards a daily SC dose of 200 IU recFSH was administered up to and including the Day of hCG.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RecFSH / Follitropin beta (Days 8 to hCG)
Description: From Stimulation Day 8 onwards a daily SC dose of 200 IU recFSH was administered up to and including the Day of hCG.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganirelix
Description: On Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganirelix
Description: On Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG
Study: NCT02290535

Intervention type: PROCEDURE
Intervention: probands
Description: Probands will receive the same treatment as patients, but without bronchospasmolysis.
Study: NCT02928406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 milligrams (mg) will be administered by intravenous (IV) infusion Q3W.
Study: NCT01515982

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: The training exercise intensity is established at 60% of VO2máx. This intensity was determined using exercise prescription guidelines established by the American College of Sports Medicine (ACSM). Each aerobic session began with a 10-minute warm-up period (40%VO2máx), followed by 20 minutes of continuous treadmill walking at an intensity established by 60% of VO2máx. The exercise session will be concluded with a 5 minutes of cool down. Heart hate (Polar® Sport Tester, Finland) and perceived exertion (Borg Scale) will be monitored and recorded at each five minutes during each exercise session by physical education instructors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Group
Description: All participants were asked not to commence any new exercise regimen.
Study: NCT02902016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GED
Description: Four duodenal biopsies will be collected. Two biopsies will stimulated with GED (PPARgamma modulator) ex vivo during 6 hours. Two biopsies will be unstimulated (control).
Study: NCT01811849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin LISPRO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin LISPRO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin LISPRO
Study: NCT03997786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildrakizumab
Description: (Weeks 16 to 52)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildrakizumab
Description: at every 12 weeks in open label fashion till 5 years (240 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildrakizumab
Description: (Weeks 0 to 16)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: (Weeks 0 to 16)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: (Weeks 16 to 52)
Study: NCT02979691

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SIB-IMRT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SIB-IMRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Study: NCT02657005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TK216
Description: Inhibitor of protein-protein interactions of EWS-FLI1 fusion protein
Study: NCT01676129

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nocipoint Therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Study: NCT01845116

Intervention type: DRUG
Group type: OTHER
Intervention: Omegaven®
Description: 10% Omegaven® initiated at a starting dose of 0.5g/kg/day for two days and then advancing to the goal dose of 1g/kg/day, IV (in the vein) until the patient no longer requires parenteral nutrition or until participation in the study is terminated.
Study: NCT02833207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug Trial 1 (EDD)
Description: Drugs that increase blood flow and test EDD are: ACh, ISO, BK, ATP. Remaining drugs used to test mechanisms of EDD: L-NMMA, ketorolac, and BaCl2.~Details under study description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug Trial 1 (EDD)
Description: Drugs that increase blood flow and test EDD are: ACh, ISO, BK, ATP. Remaining drugs used to test mechanisms of EDD: L-NMMA, ketorolac, and BaCl2.~Details under study description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug Trial 2 (ROV)
Description: Tools used to increase blood flow: muscle contractions and ATP. Remaining drugs used to test mechanisms of ROV: L-NMMA, ketorolac, and BaCl2.~Details under study description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug Trial 2 (ROV)
Description: Tools used to increase blood flow: muscle contractions and ATP. Remaining drugs used to test mechanisms of ROV: L-NMMA, ketorolac, and BaCl2.~Details under study description.
Study: NCT00136890

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET Imaging
Description: Patients randomized to PET staging will undergo FDG-PET or PET-CT as well as some form of cranial imaging (CT or MRI)
Study: NCT00925756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Maraviroc will be given dose-adjusted to background HIV treatment (150 mg, 300 mg, or 600 mg twice daily)
Study: NCT02151175

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIFUP
Study: NCT00696800

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hCG
Description: When 3 follicles \>= 17 mm were observed by USS, a single dose of 10,000 IU/USP hCG was administered; or, for those at risk for Ovarian Hyperstimulation Syndrome (OHSS), a lower dose of 5,000 IU/USP

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: hCG
Description: When 3 follicles \>= 17 mm were observed by USS, a single dose of 10,000 IU/USP hCG was administered; or, for those at risk for Ovarian Hyperstimulation Syndrome (OHSS), a lower dose of 5,000 IU/USP

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: On the day of OPU, luteal phase support was started by administering micronized progesterone of at least 600 mg/day vaginally, or at least 50 mg/day intramuscular (IM), which continued for at least 6 weeks, or up to menses.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: On the day of OPU, luteal phase support was started by administering micronized progesterone of at least 600 mg/day vaginally, or at least 50 mg/day intramuscular (IM), which continued for at least 6 weeks, or up to menses.
Study: NCT01530360

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cerebral oximeter
Description: INVOS 5100c + SAFB-SM SOMASENSOR NONIN EQUANOX 7600 + sensor model 8000CA
Study: NCT02343679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceritinib
Description: Ceritinib will be administered to ALK + hematologic malignancies orally at the 750mg/day dose that has been calculated as the maximum tolerated dose in prior phase I trials in lung cancer patients. Intra patient dose reductions will be allowed for toxicities. Subjects with stable disease or better will be allowed to continue study drug until disease progression or until intolerable adverse events or patient or physician choice.
Study: NCT01696695

Intervention type: DRUG
Intervention: Capecitabine
Description: First line capecitabine based oral tablet treatment in line with the effective Summary of Product Characteristics

Intervention type: DRUG
Intervention: Chemotherapy
Description: First line chemotherapy according to effective official Summary of Product Characteristics. The study protocol does not specify any particular therapy.
Study: NCT03604484

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tricuspid annuloplasty
Description: Tricuspid annuloplasty
Study: NCT03204578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB (Midazolam OD formulation/Dormicum)
Description: Oral disintegrating formulation (Midazolam OD Formulation). The Midazolam OD Formulation was developed by Kyukyu Pharmaceutical Co., Ltd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BA (Dormicum/Midazolam OD formulation)
Description: Oral disintegrating film (Midazolam OD Formulation). The Midazolam OD Formulation was developed by Kyukyu Pharmaceutical Co., Ltd
Study: NCT03317340

Intervention type: OTHER
Intervention: Background Sounds
Description: Background music or sound of running water
Study: NCT00509444

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational materials

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: educational materials, plus patient navigation